Basel (Switzerland) and Mannheim (Germany), January 5, 2017 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that Dr. Matthias Schroff, Chief Executive Officer, will be presenting at the 9th Annual Biotech Showcase, being held January 9-11, 2017 in San Francisco, California.
Dr. Matthias Schroff will provide an update on the Company’s business strategy and lead program, VXM01 oral T-cell immunotherapy, currently in clinical development for the treatment of colorectal cancer and glioblastoma. He will also provide insight into the Company’s technology platform to address neoantigens and other interesting targets.
The Company’s presentation will take place on Tuesday, January 10th at 10:45 AM PT. More information on the conference is available here.
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. VAXIMM’s lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is in clinical development for several tumor types, including pancreatic, colorectal and brain cancer. In addition to VXM01, VAXIMM has a pipeline of complementary development candidates targeting different tumor structures. VAXIMM’s investors include BB Biotech Ventures, Merck Ventures, Sunstone Capital and BioMed Partners. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s clinical operations. For more information, please see www.vaximm.com.
Dr. Matthias Schroff
Tel.: +49 621 8359 687 0
MC Services AG
Katja Arnold, Shaun Brown
Tel: +49 89 210228-0